Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BeOne
Content Channel
Previewing Akeso's high-stakes ASCO plenary for PD-1/VEGF
If successful, ivonescimab would be the first regimen to show a survival benefit over a PD-1/chemotherapy combo in first-line NSCLC in a phase 3 trial.
Angus Liu
May 27, 2026 11:25am
BeOne kicks off ‘One Save’ campaign with Tim Howard
May 20, 2026 6:00am
BeOne's Venclexta challenger Beqalzi nets FDA approval
May 13, 2026 4:45pm
BeOne TV drug ad hit by FDA over ‘misleading suggestions’
May 13, 2026 11:11am
Sun-Organon, Astellas, BeOne—Fierce Pharma Asia
May 1, 2026 8:43am
AZ nabs Calquence fixed-duration nod to counter BeOne’s CLL push
Feb 20, 2026 11:05am
